Article Type
Changed
Thu, 03/28/2019 - 14:54
Display Headline
Product News: 04 2017

Aktipak

Cutanea Life Sciences, Inc, launches Aktipak (erythromycin 3% and benzoyl peroxide 5%) Gel, a prescription combination therapy indicated for acne vulgaris. Aktipak is packaged in a pocket-sized, dual-chamber pouch that contains erythromycin and benzoyl peroxide in separate chambers to enable convenient on-the-go use. Immediately prior to use, the patient cuts or twists open the pouch, squeezes the 2 gels into the palm of the hand, mixes the gels together, and applies the mix to the area affected by acne. Aktipak has an 18-month shelf life and does not require refrigeration. Results can be seen within 8 weeks. For more information, visit www.aktipak.com.

Glytone Acne BPO Clearing Cleanser

Pierre Fabre Group introduces the Glytone Acne BPO Clearing Cleanser (4.5% encapsulated benzoyl peroxide [BPO]) with time-released technology to control the delivery of BPO and enhance penetration. The targeted delivery system adheres to the skin and penetrates the lipid layer while releasing the encapsulated BPO once warmed by the skin, providing optimal efficacy to inhibit the growth of acne-causing bacteria with minimal irritation. Glytone Acne BPO Clearing Cleanser is dispensed by physicians and can be used with other products in the Glytone acne product line for optimal results. For more information, visit www.glytone-usa.com.

Juvéderm Vollure XC

Allergan announces US Food and Drug Administration approval of Juvéderm Vollure XC for correction of moderate to severe facial wrinkles and folds such as the nasolabial folds in adults older than 21 years. It utilizes VYCROSS technology, which blends different weights of hyaluronic acid, contributing to the gel’s duration. Long-lasting results have been demonstrated up to 18 months. For more information, visit www.juvederm.com.

Neutrogena Light Therapy Acne Mask

Johnson & Johnson Consumer Inc presents the Neutrogena Light Therapy Acne Mask, an LED device utilizing red and blue light to treat acne at home. The mask contains 12 blue LED bulbs that kill Propionibacterium acnes bacteria and 9 red LED bulbs to penetrate deep into the skin to calm inflammation. The mask can be used for 10 minutes each night and shuts off automatically. Results have been seen in 1 week for mild to moderate acne. For more information, visit www.neutrogena.com.

3% Retinol Peel ProSystem

NeoStrata Company, Inc, introduces the 3% Retinol Peel ProSystem featuring Retinol Boosting Complex to exfoliate and improve the appearance of fine lines and winkles, help reduce acne, and improve skin laxity, while promoting a bright, even, and clear complexion. This physician-strength peel is applied in the office but is removed at home after 8 hours or overnight. This peel has demonstrated improvement in acne and skin texture as well as diminished pigmentation. For more information, visit www.neostrata.com.

Siliq

Valeant Pharmaceuticals International, Inc, announces US Food and Drug Administration approval of the Biologics License Application for Siliq (brodalumab) injection. Siliq, an IL-17 inhibitor, is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. Siliq has a black box warning for patients with a history of suicidal thoughts or behavior and was approved with a Risk Evaluation and Mitigation Strategy involving a one-time enrollment for physicians and one-time informed consent for patients. Sales and marketing in the United States will begin in the second half of 2017. For more information, visit www.valeant.com.

Thermi

Thermi, an Almirall company, announces “The Art of Thermi” campaign focusing on 2 Thermi devices: ThermiRF and Thermi250. ThermiRF is temperature-controlled radiofrequency technology that uses heat to produce aesthetic outcomes for soft tissue applications. Thermi250 is a high-powered, temperature-controlled radiofrequency system emitting at 470 kHz designed with a user-friendly interface to offer versatility for targeting cellulite. For more information, visit www.thermi.com.

If you would like your product included in Product News, please email a press release to the Editorial Office at cutis@frontlinemedcom.com.

Article PDF
Issue
Cutis - 99(4)
Publications
Topics
Page Number
267
Sections
Article PDF
Article PDF

Aktipak

Cutanea Life Sciences, Inc, launches Aktipak (erythromycin 3% and benzoyl peroxide 5%) Gel, a prescription combination therapy indicated for acne vulgaris. Aktipak is packaged in a pocket-sized, dual-chamber pouch that contains erythromycin and benzoyl peroxide in separate chambers to enable convenient on-the-go use. Immediately prior to use, the patient cuts or twists open the pouch, squeezes the 2 gels into the palm of the hand, mixes the gels together, and applies the mix to the area affected by acne. Aktipak has an 18-month shelf life and does not require refrigeration. Results can be seen within 8 weeks. For more information, visit www.aktipak.com.

Glytone Acne BPO Clearing Cleanser

Pierre Fabre Group introduces the Glytone Acne BPO Clearing Cleanser (4.5% encapsulated benzoyl peroxide [BPO]) with time-released technology to control the delivery of BPO and enhance penetration. The targeted delivery system adheres to the skin and penetrates the lipid layer while releasing the encapsulated BPO once warmed by the skin, providing optimal efficacy to inhibit the growth of acne-causing bacteria with minimal irritation. Glytone Acne BPO Clearing Cleanser is dispensed by physicians and can be used with other products in the Glytone acne product line for optimal results. For more information, visit www.glytone-usa.com.

Juvéderm Vollure XC

Allergan announces US Food and Drug Administration approval of Juvéderm Vollure XC for correction of moderate to severe facial wrinkles and folds such as the nasolabial folds in adults older than 21 years. It utilizes VYCROSS technology, which blends different weights of hyaluronic acid, contributing to the gel’s duration. Long-lasting results have been demonstrated up to 18 months. For more information, visit www.juvederm.com.

Neutrogena Light Therapy Acne Mask

Johnson & Johnson Consumer Inc presents the Neutrogena Light Therapy Acne Mask, an LED device utilizing red and blue light to treat acne at home. The mask contains 12 blue LED bulbs that kill Propionibacterium acnes bacteria and 9 red LED bulbs to penetrate deep into the skin to calm inflammation. The mask can be used for 10 minutes each night and shuts off automatically. Results have been seen in 1 week for mild to moderate acne. For more information, visit www.neutrogena.com.

3% Retinol Peel ProSystem

NeoStrata Company, Inc, introduces the 3% Retinol Peel ProSystem featuring Retinol Boosting Complex to exfoliate and improve the appearance of fine lines and winkles, help reduce acne, and improve skin laxity, while promoting a bright, even, and clear complexion. This physician-strength peel is applied in the office but is removed at home after 8 hours or overnight. This peel has demonstrated improvement in acne and skin texture as well as diminished pigmentation. For more information, visit www.neostrata.com.

Siliq

Valeant Pharmaceuticals International, Inc, announces US Food and Drug Administration approval of the Biologics License Application for Siliq (brodalumab) injection. Siliq, an IL-17 inhibitor, is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. Siliq has a black box warning for patients with a history of suicidal thoughts or behavior and was approved with a Risk Evaluation and Mitigation Strategy involving a one-time enrollment for physicians and one-time informed consent for patients. Sales and marketing in the United States will begin in the second half of 2017. For more information, visit www.valeant.com.

Thermi

Thermi, an Almirall company, announces “The Art of Thermi” campaign focusing on 2 Thermi devices: ThermiRF and Thermi250. ThermiRF is temperature-controlled radiofrequency technology that uses heat to produce aesthetic outcomes for soft tissue applications. Thermi250 is a high-powered, temperature-controlled radiofrequency system emitting at 470 kHz designed with a user-friendly interface to offer versatility for targeting cellulite. For more information, visit www.thermi.com.

If you would like your product included in Product News, please email a press release to the Editorial Office at cutis@frontlinemedcom.com.

Aktipak

Cutanea Life Sciences, Inc, launches Aktipak (erythromycin 3% and benzoyl peroxide 5%) Gel, a prescription combination therapy indicated for acne vulgaris. Aktipak is packaged in a pocket-sized, dual-chamber pouch that contains erythromycin and benzoyl peroxide in separate chambers to enable convenient on-the-go use. Immediately prior to use, the patient cuts or twists open the pouch, squeezes the 2 gels into the palm of the hand, mixes the gels together, and applies the mix to the area affected by acne. Aktipak has an 18-month shelf life and does not require refrigeration. Results can be seen within 8 weeks. For more information, visit www.aktipak.com.

Glytone Acne BPO Clearing Cleanser

Pierre Fabre Group introduces the Glytone Acne BPO Clearing Cleanser (4.5% encapsulated benzoyl peroxide [BPO]) with time-released technology to control the delivery of BPO and enhance penetration. The targeted delivery system adheres to the skin and penetrates the lipid layer while releasing the encapsulated BPO once warmed by the skin, providing optimal efficacy to inhibit the growth of acne-causing bacteria with minimal irritation. Glytone Acne BPO Clearing Cleanser is dispensed by physicians and can be used with other products in the Glytone acne product line for optimal results. For more information, visit www.glytone-usa.com.

Juvéderm Vollure XC

Allergan announces US Food and Drug Administration approval of Juvéderm Vollure XC for correction of moderate to severe facial wrinkles and folds such as the nasolabial folds in adults older than 21 years. It utilizes VYCROSS technology, which blends different weights of hyaluronic acid, contributing to the gel’s duration. Long-lasting results have been demonstrated up to 18 months. For more information, visit www.juvederm.com.

Neutrogena Light Therapy Acne Mask

Johnson & Johnson Consumer Inc presents the Neutrogena Light Therapy Acne Mask, an LED device utilizing red and blue light to treat acne at home. The mask contains 12 blue LED bulbs that kill Propionibacterium acnes bacteria and 9 red LED bulbs to penetrate deep into the skin to calm inflammation. The mask can be used for 10 minutes each night and shuts off automatically. Results have been seen in 1 week for mild to moderate acne. For more information, visit www.neutrogena.com.

3% Retinol Peel ProSystem

NeoStrata Company, Inc, introduces the 3% Retinol Peel ProSystem featuring Retinol Boosting Complex to exfoliate and improve the appearance of fine lines and winkles, help reduce acne, and improve skin laxity, while promoting a bright, even, and clear complexion. This physician-strength peel is applied in the office but is removed at home after 8 hours or overnight. This peel has demonstrated improvement in acne and skin texture as well as diminished pigmentation. For more information, visit www.neostrata.com.

Siliq

Valeant Pharmaceuticals International, Inc, announces US Food and Drug Administration approval of the Biologics License Application for Siliq (brodalumab) injection. Siliq, an IL-17 inhibitor, is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies. Siliq has a black box warning for patients with a history of suicidal thoughts or behavior and was approved with a Risk Evaluation and Mitigation Strategy involving a one-time enrollment for physicians and one-time informed consent for patients. Sales and marketing in the United States will begin in the second half of 2017. For more information, visit www.valeant.com.

Thermi

Thermi, an Almirall company, announces “The Art of Thermi” campaign focusing on 2 Thermi devices: ThermiRF and Thermi250. ThermiRF is temperature-controlled radiofrequency technology that uses heat to produce aesthetic outcomes for soft tissue applications. Thermi250 is a high-powered, temperature-controlled radiofrequency system emitting at 470 kHz designed with a user-friendly interface to offer versatility for targeting cellulite. For more information, visit www.thermi.com.

If you would like your product included in Product News, please email a press release to the Editorial Office at cutis@frontlinemedcom.com.

Issue
Cutis - 99(4)
Issue
Cutis - 99(4)
Page Number
267
Page Number
267
Publications
Publications
Topics
Article Type
Display Headline
Product News: 04 2017
Display Headline
Product News: 04 2017
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Article PDF Media